Oncology Evolved

Engineering the Next Generation of Off-the-Shelf Cell Therapies

learn about WU-CART

PIPELINE

learn more

PRE-CLINICAL

CLINICAL

CAR-T (Allogeneic)

T-ALL/LBL

T-NHL

AML

Autoimmune

LATEST NEWS

learn more

U.S. FDA Grants to Wugen’s WU-CART-007 Breakthrough Therapy Designation for Treatment of Relapsed or Refractory T Cell Acute Lymphoblastic Leukemia / T Cell Lymphoblastic Lymphoma

-- Breakthrough Therapy Designation granted to WU-CART-007 (Soficabtagene Geleucel “Sofi-cel”), an allogeneic CAR-T therapy for the treatment of T cell…

Wugen to Present Correlative Data and Long-Term Follow-Up Updates for Off-the-Shelf, Allogeneic CD7-Targeted CAR-T Cell therapy at the 2025 ASH Annual Meeting

Results from the Phase 1/2 Trial are a Foundation for the Ongoing Pivotal Study of Soficabtagene Geleucel for R/R T-Cell…

Wugen Secures $115 Million to Advance Pivotal Study of First-in-Class Allogeneic CAR-T Therapy, WU-CART-007

— Financing led by Fidelity Management & Research Company with participation from RiverVest Venture Partners, Lightchain Capital, LYZZ Capital, Abingworth,…

OPTIMIZED BY EVOLUTION

Wugen is developing off-the-shelf cellular therapies for cancer

About Wugen

Wugen is a clinical-stage biotechnology company

Science

Cellular therapies originating from healthy donors

Contact us

Get in touch with us if you have any questions